Just when I was about to start a promising new trial using 225Ac-J591, along with Keytruda + Enzalutamide -
“While early clinical results from actinium-225-based radiopharmaceuticals have been promising, the extreme global shortage of actinium-225 has slowed research and development activities and made commercialization of an actinium-225-based radiopharmaceutical very challenging,” said Dr. Joe McCann, CEO of POINT Biopharma.
I haven't been told yet that the trial will be delayed. I sure hope not. Time is not really on my side.